Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients

SUMMARY: Outcomes for melanoma patients with stage III disease differ widely even within the same subcategory. Molecular signatures that more accurately predict prognosis are needed to stratify patients according to risk. Proteomic analyses were used to identify differentially abundant proteins in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mactier, Swetlana, Kaufman, Kimberley L, Wang, Penghao, Crossett, Ben, Pupo, Gulietta M, Kohnke, Philippa L, Thompson, John F, Scolyer, Richard A, Yang, Jean Y, Mann, Graham J, Christopherson, Richard I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285183/
https://www.ncbi.nlm.nih.gov/pubmed/24995518
http://dx.doi.org/10.1111/pcmr.12290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285183/
https://www.ncbi.nlm.nih.gov/pubmed/24995518
http://dx.doi.org/10.1111/pcmr.12290

Ejemplares similares